Interferon lambda 4 expression is suppressed by the host during viral infection

Journal of Experimental Medicine

Volumn 213, Issue 12, 2016, Pages 2539-2552

  Hong, MeeAe ^a   Schwerk, Johannes ^a   Lim, Chrissie ^a   Kell, Alison ^a   Jarret, Abigail ^a   Pangallo, Joseph ^a   Loo, Yueh ming ^a   Liu, Shuanghu ^b   Hagedorn, Curt H ^c,d   Gale, Michael ^a   Savan, Ram ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; INTERFERON LAMBDA 3; INTERFERON LAMBDA 4; INTERLEUKIN 28A; INTERLEUKIN 29; NUCLEOSIDE; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; CYTOKINE RECEPTOR; IFNL4 PROTEIN, HUMAN; IFNLR1 PROTEIN, HUMAN; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; ISOPROTEIN; PATHOGEN ASSOCIATED MOLECULAR PATTERN; RECOMBINANT PROTEIN;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CANCER CELL LINE; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; COMPARATIVE STUDY; FIBROBLAST; FRAMESHIFT MUTATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ASSOCIATION STUDY; GENETIC VARIABILITY; GLYCOSYLATION; HEK293 CELL LINE; HELA CELL LINE; HEPATITIS C; HEPG2 CELL LINE; HOST; HUH7 CELL LINE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INTRON RETENTION; NONHUMAN; PH5CH8 CELL LINE; POLYADENYLATION; POLYSOME; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PSEUDOGENE; REVERSE TRANSCRIPTION; RNA ISOLATION; RNA SPLICING; SIGNAL TRANSDUCTION; STOP CODON; VIRUS INFECTION; ALTERNATIVE RNA SPLICING; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECTS; EXTRACELLULAR SPACE; GENETICS; HEPACIVIRUS; HOST PATHOGEN INTERACTION; INTRACELLULAR SPACE; METABOLISM; NUCLEOTIDE SEQUENCE; PROTEIN SYNTHESIS; TUMOR CELL LINE;

ALTERNATIVE SPLICING; ANIMALS; ANTIVIRAL AGENTS; BASE SEQUENCE; CELL DEATH; CELL LINE, TUMOR; EXTRACELLULAR SPACE; FRAMESHIFT MUTATION; HEPACIVIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERLEUKINS; INTRACELLULAR SPACE; MODELS, BIOLOGICAL; PATHOGEN-ASSOCIATED MOLECULAR PATTERN MOLECULES; PROTEIN BIOSYNTHESIS; PROTEIN ISOFORMS; RECEPTORS, CYTOKINE; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; VIRUS DISEASES;

EID: 84999633581     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20160437     Document Type: Article

References (38)

1. Aka, P.V., M.H. Kuniholm, R.M. Pfeiffer, A.S. Wang, W. Tang, S. Chen, J. Astemborski, M. Plankey, M.C. Villacres, M.G. Peters, et al. 2014. Association of the IFNL4-ag allele with impaired spontaneous clearance of hepatitis C virus. J. Infect. Dis. 209:350-354. http://dx.doi.org/10.1093/infdis/jit433
2. Amanzada, A., W Kopp, U. Spengler, G. Ramadori, and S. Mihm. 2013. Interferon-a.4 (IFNL4) transcript expression in human liver tissue samples. PLoS One. 8:e84026. http://dx.doi.org/10.1371/journal.pone.0084026
3. Bibert, S., T. Roger, T. Calandra, M. Bochud, A. Cerny, N. Semmo, FH.T. Duong, T. Gerlach, R. Malinverni, D. Moradpour, et al. Swiss Hepatitis C Cohort Study. 2013. IL28B expression depends on a novel TT/-g polymorphism which improves HCV clearance prediction. J. Exp. Med. 210:1109-1116. http://dx.doi.org/10.1084/jem.20130012
4. Booth, D., and J. George. 2013. Loss of function of the new interferon IFN-a.4 may confer protection from hepatitis C. Nat. Genet. 45:119-120. http://dx.doi.org/10.1038/ng.2537
5. Coccia, E.M., M. Severa, E. Giacomini, D. Monneron, M.E. Remoli, I. Julkunen, M. Cella, R. Lande, and G. Uze. 2004. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur. J. Immunol. 34:796-805. http://dx.doi.org/10.1002/eji.200324610
6. Contoli, M., S.D. Message, V. Laza-stanca, M.R. Edwards, P.A. Wark, N.W. Bartlett, T. Kebadze, P. Mallia, L.A. Stanciu, H.L. Parker, et al. 2006. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat. Med. 12:1023-1026. http://dx.doi.org/10.1038/nm1462
7. Crotta, S., S. Davidson, T. Mahlakoiv, C.J. Desmet, M.R. Buckwalter, M.L. Albert, P. Staeheli, and A. Wack. 2013. Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia. PLoS Pathog. 9:e1003773. http://dx.doi.org/10.1371/journal.ppat.1003773
8. Dellgren, C., H.H. Gad, OJ. Hamming, J. Melchjorsen, and R. Hartmann. 2009. Human interferon-lambda3 is a potent member of the type III interferon family. Genes Immun. 10:125-131. http://dx.doi.org/10.1038/gene.2008.87
9. Ge, D., J. Fellay, A.J. Thompson, J.S. Simon, K.V Shianna, TJ. Urban, E.L. Heinzen, P. Qiu, A.H. Bertelsen, A.J. Muir, et al. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 461:399-401. http://dx.doi.org/10.1038/nature08309
10. Hamid, F.M., and E.V Makeyev. 2014. Emerging functions of alternative splicing coupled with nonsense-mediated decay. Biochem. Soc. Trans. 42:1168-1173. http://dx.doi.org/10.1042/BST20140066
11. Hamming, O.J., E. Terczynska-dyla, G. Vieyres, R. Dijkman, S.E. Jorgensen, H. Akhtar, P. Siupka, T. Pietschmann, V Thiel, and R. Hartmann. 2013. Interferon lambda 4 signals via the IFNA receptor to regulate antiviral activity against HCV and coronaviruses. EMBOJ. 32:3055-3065. http://dx.doi.org/10.1038/emboj.2013.232
12. Jewell, N.A., T. Cline, S.E. Mertz, S.V Smirnov, E. Flano, C. Schindler, J.L. Grieves, R.K. Durbin, S.V. Kotenko, and J.E. Durbin. 2010. Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. J. Virol. 84:11515-11522. http://dx.doi.org/10.1128/JVI.01703-09
13. Keller, B.C., B.L. Fredericksen, M.A. Samuel, R.E. Mock, PW Mason, M.S. Diamond, and M. Gale Jr. 2006. Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence. J. Virol. 80:9424-9434. http://dx.doi.org/10.1128/JVI.00768-06
14. Kotenko, S.V. 2011. IFN-As. Cur. Opin. Immunol. 23:583-590. http://dx.doi.org/10.1016/j.coi.2011.07.007
15. Kotenko, S.V, G. Gallagher,'VV Baurin A. Lewis-antes M. Shen N.K. Shah J.A. Langer F. Sheikh H. Dickensheets and R.P. Donnelly. 2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4:69-77. http://dx.doi.org/10.1038/ni875
16. Liu, S., C.A. Nelson L. Xiao, L. Lu, P.P. Seth, D.R. Davis, and C.H. Hagedorn. 2011. Measuring antiviral activity of benzimidazole molecules that alter IRES RNA structure with an infectious hepatitis C virus chimera expressing Renilla luciferase. Antiviral Res. 89:54-63. http://dx.doi.org/10.1016/j.antiviral.2010.11.004
17. Lu, Y.F, D.B. Goldstein, TJ. Urban, and S.S. Bradrick. 2015a. Interferon-a4 is a cell-autonomous type III interferon associated with pre-treatment hepatitis C virus burden. Virology. 476:334-340. http://dx.doi.org/10.1016/j.virol.2014.12.020
18. Lu, Y.F., D.M. Mauger, D.B. Goldstein, TJ. Urban, K.M. Weeks, and S.S. Bradrick. 2015b. IFNL3 mRNA structure is remodeled by a functional non-coding polymorphism associated with hepatitis C virus clearance. Sci. Rep. 5:16037. http://dx.doi.org/10.1038/srep16037
19. Mahlakoiv, T., P. Hernandez, K. Gronke, A. Diefenbach, and P Staeheli. 2015. Leukocyte-derived IFN-a/p and epithelial IFN-a constitute a compartmentalized mucosal defense system that restricts enteric virus infections. PLoS Pathog 11:e1004782. http://dx.doi.org/10.1371/journal.ppat.1004782
20. McBride, D. 2013. Genetic variant links hepatitis C virus clearance and treatment response. ONS Connect. 28:50.
21. McFarland, A.P, S.M. Horner A. Jarret R.C. Joslyn E. Bindewald B.A. Shapiro D.A. Delker C.H. Hagedorn M. Carrington M. Gale Jr. and R. Savan. 2014. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat. Immunol. 15:72-79. http://dx.doi.org/10.1038/ni.2758
22. Meissner, E.G., D. Bon L. Prokunina-olsson,W. Tang, H. Masur,T.R. O'Brien, E. Herrmann, S. Kottilil, and A. Osinusi. 2014. IFNL4-ag genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J. Infect. Dis. 209:1700-1704. http://dx.doi.org/10.1093/infdis/jit827
23. Mordstein, M., G. Kochs, L. Dumoutier, J.C. Renauld, S.R. Paludan, K. Klucher, and P. Staeheli. 2008. Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog. 4:e 1000151. http://dx.doi.org/10.1371/journal.ppat.1000151
24. Mordstein, M., E. Neugebauer, V. Ditt, B. Jessen, T. Rieger, V. Falcone, F. Sorgeloos, S. Ehl, D. Mayer, G. Kochs, et al. 2010. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J. Virol. 84:5670-5677. http://dx.doi.org/10.1128/JVI.00272-10
25. Nice, T.J., M.T. Baldridge, B.T. McCune, J.M. Norman, H.M. Lazear, M. Artyomov, M.S. Diamond, and H.W Virgin. 2015. Interferon-a cures persistent murine norovirus infection in the absence of adaptive immunity. Science.347:269-273. http://dx.doi.org/10.1126/science.1258100
26. O'Brien, T.R., R.M. Pfeiffer, A. Paquin, K.A. Lang Kuhs, S. Chen, H.L. Bonkovsky, B.R. Edlin, C.D. Howell, G.D. Kirk, M.H. Kuniholm, et al. 2015. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance.J Hepatol. 63:1103-1110. http://dx.doi.org/10.1016/j.jhep.2015.06.035
27. Onabajo, O.O., P Porter-gill, A. Paquin, N. Rao, L. Liu, W. Tang, N. Brand, and L. Prokunina-olsson. 2015. Expression of interferon lambda 4 is associated with reduced proliferation and increased cell death in human hepatic cells.J. Interferon Cytokine Res. 35:888-900. http://dx.doi.org/10.1089/jir.2014.0161
28. Peiffer, K.H., L. Sommer, S. Susser, J. Vermehren, E. Herrmann, M. Doring, J. Dietz, D. Perner, C. Berkowski, S. Zeuzem, and C. Sarrazin. 2016. IFN lambda 4 genotypes and resistance-associated variants in HCV genotype 1 and 3 infected patients. Hepatology 63:63-73. http://dx.doi.org/10.1002/hep.28255
29. Pott, J., T. Mahlakoiv, M. Mordstein, C.U. Duerr, T. Michiels, S. Stockinger, P Staeheli, and M.W Hornef. 2011. IFN-lambda determines the intestinal epithelial antiviral host defense. Proc. Natl. Acad. Sci. USA. 108:79447949. http://dx.doi.org/10.1073/pnas.1100552108
30. Prokunina-olsson, L., B. Muchmore, W. Tang, R.M. Pfeiffer, H. Park, H. Dickensheets, D. Hergott, P Porter-gill, A. Mumy, I. Kohaar, et al. 2013. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 45:164-171.http://dx.doi.org/10.1038/ng.2521
31. Proudfoot, N.J. 2011. Ending the message: poly(A) signals then and now. Genes Dev. 25:1770-1782.http://dx.doi.org/10.1101/gad.17268411
32. Rauch, A., Z. Kutalik P. Descombes T. Cai J. Di Iulio T. Mueller M. Bochud M. Battegay E. Bernasconi J. Borovicka et al. 2010. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 138:1338-1345: 1345. e1-1345.e7. http://dx.doi.org/10.1053/j.gastro.2009.12.056
33. Ray, K. 2013. Hepatitis: New gene IFNL4 is associated with impaired clearance of HCV Nat. Rev. Gastroenterol. Hepatol. 10:63. http://dx.doi.org/10.1038/nrgastro.2013.7
34. Sheppard, P, W Kindsvogel W Xu K. Henderson S. Schlutsmeyer T.E. Whitmore R. Kuestner U. Garrigues C. Birks J. Roraback et al. 2003. IL-28*IL-29 and their class II cytokine receptor IL-28r. Nat. Immunol. 4:63-68. http://dx.doi.org/10.1038/ni873
35. Stone, A.E., S. Giugliano G. Schnell, L. Cheng, K.F. Leahy, L. Golden-mason, M. Gale Jr., and H.R. Rosen. 2013. Hepatitis C virus pathogen associated molecular pattern (PAMP) triggers production of lambda-interferons by human plasmacytoid dendritic cells. PLoS Pathog. 9:e1003316. http://dx.doi.org/10.1371/journal.ppat.1003316
36. Suppiah, V., M. Moldovan, G. Ahlenstiel, T. Berg, M. Weltman, M.L. Abate, M. Bassendine, U. Spengler, G.J. Dore, E. Powell, et al. 2009. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 41:1100-1104. http://dx.doi.org/10.1038/ng.447
37. Suthar, M.S., D.Y. Ma, S. Thomas, J.M. Lund, N. Zhang, S. Daffis, A.Y. Rudensky, M.J. Bevan, E.A. Clark, M.K. Kaja, et al. 2010. IPS-1 is essential for the control ofWest Nile virus infection and immunity. PLoS Pathog. 6:e1000757. http://dx.doi.org/10.1371/journal.ppat.1000757
38. Tanaka, Y., N. Nishida, M. Sugiyama, M. Kurosaki, K. Matsuura, N. Sakamoto, M. Nakagawa, M. Korenaga, K. Hino, S. Hige, et al. 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41:1105-1109. http://dx.doi.org/10.1038/ng.449